Page 147 - CSIR-IGIB Annual Report 2020-21

Cancer-Immunotheragnostics Although, the remarkable clinical benefits have
We use clinical proteomics and metabolomics as a been observed with immune checkpoint blockers
major research tool for early detection, in some tumor types but only in a small number of
prognostication and predictive bio-marker patients. Further it was reported that tumor cell
discovery for different types of cancer. One of the suppresses the metabolism of immune cell to
major research goals of our laboratory is to dampen its functionality. Henceforth, to decode
elucidate the novel immunotherapeutic target by these ambiguities regarding the individual specific
immuno-metabolomics & proteomics approach. immunotherapeutic response as well as the
Our laboratory is actively collaborating with sTata metabolic competition & co-operation amongst
Medical Center, Stanford University USA, Bruker- tumor cells and various types of immune cells in
Germany & IIT Kharagpur for cancer research. the heterogeneous niche of tumor
Immuno-metabolomics & proteomics is an microenvironment, detailed immune
evolving field to explore a new dimension of metabolomics & proteomics study is necessary.
immunology which attributes a promising impact Therefore, our lab is extensively working on cancer
in targeted immune-theragnosis. In recent years, proteomics & metabolomics with special
cancer-immunotherapy has been reflected with reference to immunotherapeutic target
great success, but only for a few types of identification considering spatiotemporal
carcinomas like melanoma, breast, head-neck, and attributes in single-cell resolution in the backdrop
lung. Check-point blockade therapy is one of the of clinical findings.
most notable immunotherapies in recent times.

Publications

Flavonoids as potential phytotherapeutics to combat cytokine storm in SARS-CoV-2. Gour A, Manhas D, Bag S, Gorain B,
Nandi U. Phytother Res. 2021 Aug;35(8):4258-4283.

Annual Report 2020-21 144